Optiscan Imaging Ltd
ASX:OIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (38.4), the stock would be worth AU$-0.26 (341% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16 | AU$0.11 |
0%
|
| Industry Average | 38.4 | AU$-0.26 |
-341%
|
| Country Average | 18.1 | AU$-0.12 |
-213%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Optiscan Imaging Ltd
ASX:OIL
|
114.9m AUD | -16 | -15.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 65.3 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 20.7 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 27.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 29.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 37 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 46 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 17.2 | 20.1 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 12.5 |
| Median | 18.1 |
| 70th Percentile | 35.6 |
| Max | 5 049.1 |
Other Multiples
Optiscan Imaging Ltd
Glance View
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The company is headquartered in Mulgrave, Victoria. The firm has developed and commercialized confocal microscopes for clinical and pre-clinical applications. Its endomicroscopic technology enables 3D, in-vivo imaging of human tissue at the cellular level for cancer screening, diagnoses and in surgery. Its InVivage device is developed for clinical use in the oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a miniaturised confocal endomicroscope used for cellular level in-vivo imaging in living tissues. The firm also provides customization options for its product, (FIVE2).
